Kornimate/medical-research-clean huggingface dataset:
safety and efficacy of aprepitant for cinv in patients with lung cancer receiving multiple-day cisplatin chemotherapy

Conditions: Chemotherapy-Induced Nausea and Vomiting; Lung Cancer

Summary: aprepitant is an oral neurokinin-1(nk-1) antagonist which is used for the prevention of chemotherapy-induced nausea and vomiting (cinv). this phase ii clinical trial was designed to evaluate the efficacy of aprepitant in the prevention of cinv with lung cancer patients receiving 3-day cisplatin-based chemotherapy.

patients pathologic diagnosed of advanced non-small cell lung cancer, according to nccn non-small cell lung cancer guide line(2015 v1).the patient should receive a 3-day cisplatin-based chemotherapy, are randomized divided into two groups, aprepitant group and placebo group. in aprepitant group, patients would receive aprepitant(125 mg po at day1, 80 mg at day2-3) combination with palonosetron and dexamethasone(5mg iv at day1-3, 3.75mg po at day4-5). in placebo group patients would receive palonosetron and dexamethasone(5mg iv at day1-3, 7.5mg po at day4-5).during the treatment, any grade of nausea and vomiting should be recorded in order to evaluate the complete response rate of cinv, other side-effects should be recorded.

Eligibility criteria:
inclusion criteria: 1. patient who was confirmed lung cancer by pathologic histology or cytology. 2. males or females aged ≥18 years, \<80 years. 3. eastern cooperative oncology group (ecog) performance status 0-2. life expectancy ≥12 weeks. 4. males and females should be contraceptive during the period of the trial until 8 weeks after the last administration of the drug. 5. patients with asymptomatic, treated brain metastases are eligible for trial participation. 6. adequate bone marrow, renal, and liver function are required. 7. able to comply with the required protocol and follow-up procedures, and able to receive oral medications. 8. institutional review board-approved informed consent will be obtained for every patient before initiation of any trial-specific procedure or treatment. exclusion criteria: 1. history of sensitivity/idiosyncrasy to aprepitant or excipients 2. condition that might interfere with drug absorption, distribution metabolism or excretion. 3. concomitant use of agents that are known to interfere with aprepitant pharmacokinetics 4. any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease). 5. lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or have active peptic ulcer disease. 6. female subjects should not be pregnant or breast-feeding. 7. inadequate hematological function. 8. abnormal liver and renal function. 9. patient assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.

Keywords: nausea vomiting chemotherapy-induced nausea and vomiting cinv aprepitant lung cancer
assessment of visual performance combining a symfony iol and a +3.25 tecnis multifocal iol

Conditions: Cataract

Summary: this will be a single center, non comparison clinical trial. fifty study patients will have the symfony iol implanted in their dominant eye and a +3,25d tecnis multifocal in their non-dominant eye. the investigators will be evaluated vision at distance, intermediate and near as well as assessing patient satisfaction and spectacle independence.

each study patient will undergo the same routine cataract extraction procedure in each eye. in their dominant eye a tecnis symfony iol will be implanted and in the non dominant eye, a tecnis +3.25d multifocal implanted. the surgeries will be within 2 days of each other. every patient will receive same postoperative instructions and medications. the aim is to investigate the potential benefits of implanting two different iol's to give the patient a wider range of near vision with decreased risk of haloing and glare to enable them to be less dependent on reading glasses

Eligibility criteria:
inclusion criteria: * good general health, * willing to comply with study instructions, * visual potential of 20/30 or better, * less than 1.5d of corneal astigmatism, * normal macula, * clear lens or cataract, * pupil size greater than 3.5mm exclusion criteria: * known pathology to affect visual outcome, * amblyopia or strabismus, * pupil abnormalities, * zonule problems, * keratoconus, * no prior ocular surgery,use of medication that could affect vision, * uncontrolled systemic disease
the hemophilia inhibitor eradication trial

Conditions: Hemophilia A With Inhibitor

Summary: this is a multi-center randomized phase iii clinical trial, the inhibitor eradication trial, in which eloctate iti plus emicizumab will be compared with eloctate iti alone to eradicate inhibitors in severe hemophilia a.

this is a multi-center randomized phase iii clinical trial, the inhibitor eradication trial, in which eloctate iti plus emicizumab will be compared with eloctate iti alone to eradicate inhibitors in patients with severe hemophilia a this adaptive design is necessary as randomized trials in rare diseases are often not possible. the inhibit clinical trials platform includes two linked trials, the inhibitor prevention trial (prevention trial) and the inhibitor eradication trial (eradication trial) that will be conducted at up to 41 u.s. hemophilia treatment centers (htcs) affiliated with universities. the inhibitor eradication trial is a 48-week randomized phase iii trial, in which 90 previously treated patients (ptps) with severe hemophilia a and high-responding inhibitors (anti-viii \> 0.6 b.u.), will be enrolled. subjects will include individuals with severe hemophilia a who develop inhibitors during the linked inhibitor prevention trial and adults or children at the same htcs refractory to or never undergoing immune tolerance induction (iti). once enrolled, subjects who meet all the inclusion and none of the exclusion criteria, will be randomized to weekly eloctate iti plus weekly emicizumab vs. weekly eloctate iti alone to eradicate inhibitor formation, defined as anti-fviii\<0.6 b.u. blood draws will be minimized to 6 timepoints, pre, 4, 12, 24, 36, and 48 weeks, and validated for small volumes, 3.8 cc (¾ tsp) each. the inhibitor eradication trial is considered greater than minimal risk as study drug is given before the first bleed and special inhibitor studies are obtained. (nb: the inhibitor eradication trial (pro19070080) is linked to the inhibitor prevention trial (pro19040140), as part of the inhibit clinical trials platform, and both trials will be conducted efficiently in the same hemophilia treatment centers (htcs), with the same mds, coordinators, visit frequency, blood sampling, and assays.

Eligibility criteria:
inclusion criteria: 1. male adults or children \> 4 months of age. 2. severe hemophilia a (fviii \< 0.01 u/ml). 3. current or past high-responding inhibitor, anti-fviii \>= 5.0 b.u., iti-refractory or iti-naive. exclusion criteria: 1. acquired hemophilia or any bleeding disorder other than hemophilia a. 2. current use of emicizumab, or if used, \> 8 weeks since last treatment. 3. use of an experimental drug(s). 4. surgery anticipated in the next 48 weeks. 5. life expectancy less than 5 years. 6. patient/parent/caretaker unable or unwilling to keep a personal diary of bleeding frequency and study drug treatment, make monthly visits and blood draws at weeks 4, 8, 12, 24, 36, and 48. 7. other illness, condition, or reason in the opinion of the investigator that would make the patient unsuitable for the trial.

Keywords: hemophilia inhibitor formation eloctate emicizumab
carbohydrate antigen 19-9 in colorectal cancer

Conditions: Colorectal Cancer

Summary: 4,972 patients who underwent surgery for primary crc between january 2004 and december 2015 at seoul national university hospital were retrospectively reviewed. ca19-9 is a valuable prognostic and diagnostic marker for crc when used adjunctively with cea and can be a supplementary marker with cea to improve sensitivity, especially with elevated preoperative ca19-9.

introduction: carcinoembryonic antigen (cea) is a main prognostic marker and can detect colorectal cancer (crc) recurrence, but it has low sensitivity. carbohydrate antigen 19-9 (ca19-9) can be used as a supplemental tumour marker along with cea. this study investigated the utility of preoperative and follow-up serum ca19-9 assessment for crc. materials and methods: we retrospectively assessed 4,972 patients who underwent surgery for primary crc between january 2004 and december 2015 at seoul national university hospital. data on demographics, preoperative and follow-up cea and ca19-9 levels, recurrence, and survival were obtained and analysed with respect to tumour marker levels to ascertain their prognostic and diagnostic values. results: the 5-year relapse-free survival rates were 72.2±0.8%, 52.5±2.2%, 55.5±3.2%, and 32.1±2.3% in the normal cea and ca19-9, high cea, high ca19-9, and high cea and high ca19-9 groups, respectively (all p\<0.001). patients whose elevated cea or ca19-9 reduced to normal had better survival outcomes than those with postoperatively elevated levels. elevated follow-up ca19-9 and cea levels were related to higher incidences of distant metastasis (ca19-9: 14.0% vs. 23.1%, p=0.004, cea: 12.6% vs. 30.1%, p\<0.001) but not with local recurrence. combined follow-up cea and ca19-9 increased the sensitivity for recurrence to 31.4%, with a 5% difference compared with cea alone. in the subgroup with high preoperative ca19-9 levels, sensitivity increased by 18.2% overall. conclusion: ca19-9 is a valuable prognostic and diagnostic marker for crc when used adjunctively with cea and can be a supplementary marker with cea to improve sensitivity, especially with elevated preoperative ca19-9.

Eligibility criteria:
inclusion criteria: * patients who underwent surgery for primary crc between january 2004 and december 2015 at seoul national university hospital exclusion criteria: * the patients with missing data for preoperative and follow-up tumour markers
vestibular rehabilitation for patients with fall-related wrist fractures

Conditions: Wrist Fractures; Dizziness

Summary: dizziness has been identified as a risk factor for fall and vestibular asymmetry has been found among patients with fall-related wrist fractures as well as among patients with hip-fracture. since wrist fracture is a risk factor for hip-fracture, much effort is focused on preventing falls for risk-groups. therefore, it would be interesting to find out if it is possible to influence vestibular asymmetry with vestibular rehabilitation. the aim of this study is therefore to find out if vestibular rehabilitation can have any effect on vestibular function among patients with fall-related wrist fracture.

fall-related fractures are an increasing problem for the society. almost 30% of persons over 65 years of age fall each year. in sweden 627 persons out of 100 000 is treated in hospitals because of injury after a fall. in malmö, the figure is 883 persons out of 100 000. however, not all falls lead to a fracture. dizziness has been identified as a risk factor for fall and vestibular asymmetry has been found among patients with fall-related wrist fractures as well as among patients with hip-fracture. vestibular rehabilitation programs were first developed in the forties, originally used for peripheral vestibular disorder, in order to facilitate recovery. modern research has widened the use of vestibular rehabilitation to patients with other causes of dizziness than peripheral vestibular disorders. since wrist fracture is a risk factor for hip-fracture, much effort is focused on preventing falls for risk-groups. therefore, it would be interesting to find out if it is possible to influence vestibular asymmetry with vestibular rehabilitation. the aim of this study is therefore to find out if vestibular rehabilitation can have any effect on vestibular function among patients with fall-related wrist fracture.

Eligibility criteria:
inclusion criteria: * fall-related wrist fracture * 50 years or older exclusion criteria: * younger than 50 * wrist fracture not related to fall

Keywords: wrist fractures vestibular asymmetry vestibular rehabilitation fall-related wrist fractures patients 50 years or older
evaluation of autogenous demineralized dentin graft for ridge preservation with and without injectable platelet rich fibrin

Conditions: Ridge Preservation; Alveolar Bone Loss; Dentin Graft

Summary: ridge preservation should be considered whenever possible after tooth extraction. whether implant placement would be performed or for aesthetic consideration at pontic sites when conventional bridge is planned. ridge preservation aims to maximize the bone formation accompanied with good soft tissue architecture to facilitate implant and prosthetic replacement restoring function, phonetics and aesthetics. the aim of the study is to evaluate the bucco-lingual ridge width clinically and radiographically, height of buccal and lingual ridges of the socket after application of injectable platelet rich fibrin and autogenous dentin graft.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years need of at least one single rooted tooth extraction. * non-restorable teeth. * systemically healthy patients. * good oral hygiene, plaque index less than 15%. * non-smoker or smoking ≤ 10 cigarettes/day. * cooperative patients able and accept to come for follow up appointments. exclusion criteria: * any interim intervention that may have affected any of the outcomes of interest. * pregnant and lactation females. * smoking ˃ 10 cigarettes/day. * patients reporting systemic conditions that may compromise healing or bone metabolism (eg: diabetes). * patients with poor oral hygiene. * any known allergies.
long-term patient satisfaction of facial aesthetic treatment with botox®

Conditions: Glabellar Lines

Summary: this is an observational study assessing patient satisfaction following at least 5 years of botox® treatment for glabellar lines.


Eligibility criteria:
inclusion criteria: * at least one botox® treatment for facial wrinkles (glabellar lines) per calendar year for ≥5 years exclusion criteria: * received botulinum toxin formulations other than botox®
feasibility of mutational analysis of non-small cell lung cancer (nsclc) using low-volume lung aspirates

Conditions: Lung Cancer

Summary: the purpose of this study is to evaluate the feasibility of aspiration samples for mutational analysis in patients with a non-small cell lung cancer (nsclc).

the investigators will compare results of mutational analysis from a core needle biopsy and fine needle aspiration.

Eligibility criteria:
inclusion criteria: * primary tumor or a metastatic lung lesion requested for mutational analysis exclusion criteria: * a) lesions located adjacent to the large central bronchi or vessels * b) peribronchovascular lesions with prominent internal ct air-bronchograms, which were considered difficult to be avoided by needle pass * c) lesions in patient with severe respiratory compromise

Keywords: biopsy needle aspiration mutational analysis
effects of down dog yoga on pre-writing skills in children with down syndrome

Conditions: Down Syndrome

Summary: down syndrome is a genetic condition caused by an extra chromosome 21, affecting physical and cognitive development. this study will evaluate the effects of down dog yoga on prewriting skills in children with down syndrome aged 4-8 years. a randomized controlled trial with 32 participants will be conducted at bahawal victoria hospital over 10 months. assessments will include jthft, bbt, and the prewriting skills scale.

down syndrome is a genetic condition where people are born with an extra chromosome. most people have 23 pairs of chromosomes within each cell in their body, for a total of 46. a person diagnosed with down syndrome has an extra copy of chromosome 21, which means their cells contain 47 total chromosomes instead of 46. this changes the way their brain and body develop. down syndrome causes physical, cognitive and behavioral symptoms. down syndrome occurs in approximately 1 in 1,000 to 1 in 1,100 live births globally. each year, around 3,000 to 5,000 children are born with this genetic condition characterized by an extra chromosome. children with down syndrome may experience challenges with fine motor skills because of low muscle tone or hypermobility in their hands, wrists, or elbows. this instability in their hands can significantly hinder their ability to perform advanced fine motor tasks such as prewriting, using zippers and buttons, or cutting. early intervention refers to a structured approach involving therapy, exercises, and activities aimed at addressing developmental delays in children with down syndrome or other disabilities. for addressing pre writing skills in down syndrome down dog yoga will be provided. the study design will be randomized controlled trial and will be conducted in bahawal victoria hospital with the sample size of 34, age ranging 4 to 8 years. this study will be completed in time duration of 10 months after the approval of synopsis. non-probability convenient sampling technique will be used and participants will be recruited in study after randomization. the subjects will be divided into two groups i.e one being experimental group and the other control group. inclusion criteria will be including both genders of age group 4 to 8 years of children with down syndrome and exclusion criteria will be any deformity, injury any previous 6 month surgery. tools will be jebsen-taylor hand function test (jthft) , box and block test (bbt) and pre writing skills scale. reliability of jthft is 0.9, bbt is \>0.95 and pre writing skills is 0.91 with high variability in writing performance.

Eligibility criteria:
inclusion criteria: * children with age group 4-8years * both genders (male female) * children who can do independent standing and walking exclusion criteria: * any deformity * pain and/or symptomatic neurologic/orthopedic dysfunction of upper or lower extremities * cervical injury and chest wall disorders * injury * fractures * history of previous surgery * children with impaired fun

Keywords: down dog yoga jthft bbt pre-writing skills
effect of liraglutide as add-on to metformin compared to either liraglutide or metformin alone, or to a combination of metformin and a su (sulphonylurea) agent in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe and oceania. the aim of this trial is to assess the effect on glycemic control of nnc 90-1170 (liraglutide) added to metformin compared to metformin given alone in subjects with type 2 diabetes previously treated with ohas (oral hypoglycaemic agents).


Eligibility criteria:
inclusion criteria: * patients diagnosed with type 2 diabetes and treated with at least 50 % of maximum dose(s) of oha(s) for at least three months * duration of type 2 diabetes diagnosis at least one year * hba1c 8.0-13.0%, both inclusive * body mass index (bmi) between 25-40 kg/m\^2, both inclusive. exclusion criteria: * current treatment with thiazolidinediones or insulin initiated within the last four months prior to trial * impaired liver function * impaired renal function * cardiac problems * uncontrolled treated/untreated hypertension * cancer or any clinically significant disease or disorder, except for conditions associated to the type 2 diabetes, which in the investigator's opinion could interfere with the results of the trial * recurrent major hypoglycaemia as judged by the investigator * known or suspected allergy to trial product or related products * use of any drug (except for ohas), which in the investigator's opinion could interfere with the glucose level * known or suspected abuse of alcohol or narcotics * any contraindications to metformin or glimepiride according to the local guidelines
total intravenous anesthesia in percutaneous transhepatic cholangiography

Conditions: Percutaneous Transhepatic Cholangiography

Summary: percutaneous transhepatic cholangiography is a disturbing procedure for patients. tiva with short-acting anesthetics such as propofol and remifentanil is characterized by hemodynamic stability and better compilation profile the purpose of this study; to compare total intravenous anesthesia with inhalation anesthesia in patients undergoing percutaneous transhepatic cholangiography under general anesthesia.

percutaneous transhepatic cholangiography is a disturbing procedure for patients. especially pain at the time of dilation can be a serious problem. these situations may be required local anesthetics, intravenous narcotics and sedatives or general anesthesia (1). tiva with short-acting anesthetics such as propofol and remifentanil is characterized by hemodynamic stability and better compilation profile (2). the purpose of this study; to compare total intravenous anesthesia with inhalation anesthesia in patients undergoing percutaneous transhepatic cholangiography under general anesthesia and determine their advantages and disadvantages. 1. michael j. lee, peter r. mueller, sanjay saini, peter f. hahn, stewen l. dawson. percutaneous dilatation of benign biliary strictures: single-season therapy with general anesthesia. ajr: 157, december 1991: 1263-1266 2. xiaoqian deng, tao zhu. clinical comparison of propofol-remifentanil tci with sevoflurane induction / maintenance anesthesia in laparoscopic cholecystectomy. pak j med sci 2014 vol. 30 no. 5: 1017-1021

Eligibility criteria:
inclusion criteria: * adult patients undergoing percutaneous transhepatic cholangiography with general anesthesia exclusion criteria: * essential data were missing * patient participating in other research projects * drug allergy * anesthetic complication story

Keywords: quality of anesthesia reduce recovery time